Analysts Expect Can Fite Biopharma Ltd (CANF) to Announce ($0.14) Earnings Per Share
Can Fite Biopharma Ltd (NASDAQ:CANF) has been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.
Analysts have set a 1-year consensus price objective of $7.50 for the company and are expecting that the company will post ($0.14) EPS for the current quarter, according to Zacks. Zacks has also assigned Can Fite Biopharma an industry rank of 100 out of 265 based on the ratings given to its competitors.
A number of research analysts recently weighed in on the stock. Maxim Group reissued a “buy” rating and set a $7.00 price target on shares of Can Fite Biopharma in a research report on Monday, September 18th. HC Wainwright set a $6.00 price target on shares of Can Fite Biopharma and gave the company a “buy” rating in a research report on Thursday, August 10th.
Shares of Can Fite Biopharma (NASDAQ:CANF) traded up 0.60% during midday trading on Monday, reaching $1.69. 15,516 shares of the company’s stock traded hands. The stock has a 50 day moving average of $1.69 and a 200-day moving average of $1.78. The stock’s market cap is $29.34 million. Can Fite Biopharma has a 12 month low of $1.50 and a 12 month high of $2.68.
Can Fite Biopharma Company Profile
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Can Fite Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.